- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease
December 11, 2023
Tickers
AZN
From Benzinga
Tickers
AZN
From Motley Fool
From MarketWatch
From Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
From Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
From Benzinga
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
December 01, 2023
Tickers
AZN
From Benzinga
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
November 27, 2023
Tickers
AZN
From Benzinga
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
November 22, 2023
Tickers
AZN
From Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
November 22, 2023
From Motley Fool
5 Growth Stocks to Buy for 2024
November 20, 2023
From InvestorPlace
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
November 17, 2023
From Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
November 17, 2023
From Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
From Benzinga
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
From Benzinga
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
November 14, 2023
Tickers
AZN
From Benzinga
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
November 13, 2023
From InvestorPlace
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
November 13, 2023
Tickers
AZN
From Benzinga
Who’s afraid of Ozempic? From restaurants to package makers, companies work to calm investors’ GLP-1 jitters.
November 10, 2023
From MarketWatch
From InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
November 09, 2023
Tickers
AZN
From Motley Fool
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
November 09, 2023
Tickers
AZN
From Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
November 09, 2023
From Benzinga
Virgin Galactic shares surge as space firm doubles revenue while Walt Disney stock jumps on spike in streaming customers
November 09, 2023
From MarketWatch
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
November 09, 2023
Tickers
AZN
From MarketWatch
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
November 06, 2023
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.